Posted on April 1, 2021 by Sitemaster
According to a recent article in Modern Pathology, a team of researchers at Yale University and at Memorial Sloan-Kettering Cancer Center (MSKCC) have been able to show that an artificial intelligence (AI) system designed and validated at MSKCC could be used to diagnose prostate cancer as either “suspicious” or “not suspicious” based on data from nearly 2,000 slides of prostate tissue acquired at Yale Medicine. … READ MORE …
Filed under: Diagnosis, Risk | Tagged: AI, artificial, biopsy, intelligence, pathology, slide | 4 Comments »
Posted on October 18, 2018 by Sitemaster
There is no longer any doubt that men initially diagnosed with low- and very low-risk forms of prostate cancer are, in most cases, either excellent or good candidates for first-line management on active surveillance (AS). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, advese, AS, favorable, pathology, risk, surveillance, unfavorable | 7 Comments »
Posted on November 29, 2017 by Sitemaster
Here is a link to a clever article by a pathologist in the Chicago suburbs who spends a lot of his working days deciding whether he can or can’t see prostate cancer cells in the biopsy samples sent to his laboratory. It makes a good read. … READ MORE …
Filed under: Diagnosis | Tagged: pathology | 5 Comments »
Posted on July 22, 2017 by Sitemaster
It would be easy to misinterpret (or at least “over-interpret”) a recent paper from the group at Johns Hopkins about the pathological outcomes of men initially diagnosed with very low-, low-, or “favorable” intermediate-risk localized disease and treated by immediate radical prostatectomy. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, definable, pathology, risk, subset, surgery, surveillance | 23 Comments »
Posted on March 2, 2017 by Sitemaster
Various forms of focal therapy are now being used by some physicians to treat selected patients with well-identified, usually relatively small, “dominant” or “index” tumors that are confined to highly defined areas of the prostate. … READ MORE …
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: focal, pathology, patient. selection, review, therapy | 4 Comments »
Posted on February 26, 2016 by Sitemaster
It has long between understood that there is an association between a man’s serum levels of vitamin D and his risk for prostate cancer in general and clinically significant prostate cancer in particular. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: adverse, pathology, radical prostatectomy, risk, vitamin D | 6 Comments »
Posted on September 7, 2015 by Sitemaster
An interesting — if unsurprising — new set of data in the Journal of Korean Medical Science has again shown that most of the current “standard” sets of criteria for selection of patients aren’t even close to being perfect at identification of “the surgically ideal” patients for management on active surveillance. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, criteria, outcome, pathology, surveillance | 2 Comments »
Posted on August 3, 2015 by Sitemaster
A recent article in the Journal of Clinical Pathology reviews available data about the epidemiology, biology, and clinical pathology of “young age” prostate cancer, which the authors define as clinically significant cancer in men under 55 years of age. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: age, biology, epidemiology, pathology, risk, young | Leave a comment »
Posted on June 10, 2015 by Sitemaster
In the most recent issue of AUA News, Dr. Jonathon Epstein of Johns Hopkins — unarguably one of the world’s leading prostate cancer pathologists — has laid out the general principles behind a new, validated, prostate cancer grading system that is designed and intended to replace the traditional Gleason grading system over the next few years. … READ MORE …
Filed under: Diagnosis, Management, Risk | Tagged: grading, histology, pathology | 27 Comments »
Posted on May 2, 2015 by Sitemaster
A recent report in European Urology found that, in spite of three randomized clinical trials (RCTs) that proved the efficacy of immediate or adjuvant radiation following surgery with adverse pathology results compared to a wait-and-see approach, a lower percentage of such patients are actually getting adjuvant treatment. Why should this be? … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: adjuvant, adverse, pathology, post-surgery, radiation | 2 Comments »
Posted on December 18, 2014 by Sitemaster
Now here’s some data that may cause a bit of a furore … so before the US-based urologists get upset, we’d like to point out that this is a Canadian study based on data from members of the Canadian urology community in a single, unidentified Canadian province! … READ MORE …
Filed under: Management, Treatment | Tagged: outcome, pathology, practice, site, surgery, training | 5 Comments »
Posted on December 12, 2014 by Sitemaster
As previously mentioned earlier this week, a long statement that deals with the role of the pathologist in determining the suitability of patients for enrollment into active surveillance management protocols has been issued and endorsed by a number of organizations. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, consensus, Diagnosis, Management, pathology, risk, surveillance | 6 Comments »
Posted on December 9, 2014 by Sitemaster
A paper in the journal Virchows Archiv suggests increasing consensus on both inclusion criteria for management on active surveillance and progression criteria suggesting the need for active treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, consensus, pathology, surveillance | 6 Comments »
Posted on June 27, 2013 by Sitemaster
A new study in the Journal of Clinical Oncology has suggested that African American men with very low-risk disease (according to the National Comprehensive Cancer Network or NCCN definition) are at higher risk for disease progression than comparable Caucasian patients if they follow active surveillance protocols. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active surveillance, outcome, pathology, race, risk, surgery | Leave a comment »
Posted on December 20, 2012 by Sitemaster
A new paper from clinical research teams at two French hospitals suggests that there has been a significant relative increase (from 2005 to 2010, at their institutions) in the percentage of men found to have pathological T3 as opposed to pathological T2 disease after radical prostatectomy (RP). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: grade, pathology, radical prostatectomy, risk, stage, surgery | 1 Comment »
THE "NEW" PROSTATE CANCER INFOLINK 